Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas by Hartmann, C et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Type and frequency of IDH1 and IDH2 mutations are related to
astrocytic and oligodendroglial differentiation and age: a study of
1,010 diffuse gliomas
Hartmann, C; Meyer, J; Balss, J; Capper, D; Mueller, W; Christians, A; Felsberg, J;
Wolter, M; Mawrin, C; Wick, W; Weller, M; Herold-Mende, C; Unterberg, A; Jeuken,
J W M; Wesseling, P; Reifenberger, G; von Deimling, A
Hartmann, C; Meyer, J; Balss, J; Capper, D; Mueller, W; Christians, A; Felsberg, J; Wolter, M; Mawrin, C; Wick,
W; Weller, M; Herold-Mende, C; Unterberg, A; Jeuken, J W M; Wesseling, P; Reifenberger, G; von Deimling, A
(2009). Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial
differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica, 118(4):469-474.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Acta Neuropathologica 2009, 118(4):469-474.
Hartmann, C; Meyer, J; Balss, J; Capper, D; Mueller, W; Christians, A; Felsberg, J; Wolter, M; Mawrin, C; Wick,
W; Weller, M; Herold-Mende, C; Unterberg, A; Jeuken, J W M; Wesseling, P; Reifenberger, G; von Deimling, A
(2009). Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial
differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica, 118(4):469-474.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Acta Neuropathologica 2009, 118(4):469-474.
Type and frequency of IDH1 and IDH2 mutations are related to
astrocytic and oligodendroglial differentiation and age: a study of
1,010 diffuse gliomas
Abstract
Somatic mutations in the IDH1 gene encoding cytosolic NADP+-dependent isocitrate dehydrogenase
have been shown in the majority of astrocytomas, oligodendrogliomas and oligoastrocytomas of WHO
grades II and III. IDH2 encoding mitochondrial NADP+-dependent isocitrate dehydrogenase is also
mutated in these tumors, albeit at much lower frequencies. Preliminary data suggest an importance of
IDH1 mutation for prognosis showing that patients with anaplastic astrocytomas, oligodendrogliomas
and oligoastrocytomas harboring IDH1 mutations seem to fare much better than patients without this
mutation in their tumors. To determine mutation types and their frequencies, we examined 1,010 diffuse
gliomas. We detected 716 IDH1 mutations and 31 IDH2 mutations. We found 165 IDH1 (72.7%) and 2
IDH2 mutations (0.9%) in 227 diffuse astrocytomas WHO grade II, 146 IDH1 (64.0%) and 2 IDH2
mutations (0.9%) in 228 anaplastic astrocytomas WHO grade III, 105 IDH1 (82.0%) and 6 IDH2
mutations (4.7%) in 128 oligodendrogliomas WHO grade II, 121 IDH1 (69.5%) and 9 IDH2 mutations
(5.2%) in 174 anaplastic oligodendrogliomas WHO grade III, 62 IDH1 (81.6%) and 1 IDH2 mutations
(1.3%) in 76 oligoastrocytomas WHO grade II and 117 IDH1 (66.1%) and 11 IDH2 mutations (6.2%) in
177 anaplastic oligoastrocytomas WHO grade III. We report on an inverse association of IDH1 and
IDH2 mutations in these gliomas and a non-random distribution of the mutation types within the tumor
entities. IDH1 mutations of the R132C type are strongly associated with astrocytoma, while IDH2
mutations predominantly occur in oligodendroglial tumors. In addition, patients with anaplastic glioma
harboring IDH1 mutations were on average 6 years younger than those without these alterations.
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Abstract 
 
Somatic mutations in the IDH1 gene encoding cytosolic NADP+ dependent isocitrate dehydrogenase 
have been shown in the majority of astrocytomas, oligodendrogliomas and oligoastrocytomas of WHO 
grades II and III. IDH2 encoding mitochondrial NADP+ dependent isocitrate dehydrogenase also is 
mutated in these tumors, albeit at much lower frequencies. Preliminary data suggest an importance of 
IDH1 mutation for prognosis showing that patients with anaplastic astrocytomas, oligodendrogliomas 
and oligoastrocytomas harbouring IDH1 mutations seem to fare much better than patients without this 
mutation in their tumors. To determine mutation types and their frequencies, we examined 1010 
diffuse gliomas. We detected 716 IDH1 mutations and 31 IDH2 mutations. We found 165 IDH1 
(72.7%) and 2 IDH2 mutations (0.9%) in 227 diffuse astrocytomas WHO grade II, 146 IDH1 (64.0%) 
and 2 IDH2 mutations (0.9%) in 228 anaplastic astrocytomas WHO grade III, 105 IDH1 (82.0%) and 6 
IDH2 mutations (4.7%) in 128 oligodendrogliomas WHO grade II, 121 IDH1 (69.5%) and 9 IDH2 
mutations (5.3%) in 174 anaplastic oligodendrogliomas WHO grade III, 62 IDH1 (81.6%) and 1 IDH2 
mutations (1.3%) in 76 oligoastrocytomas WHO grade II and 117 IDH1 (66.1%) and 9 IDH2 mutations 
(5.1%) in 177 anaplastic oligoastrocytomas WHO grade III. We report on an inverse association of 
IDH1 and IDH2 mutations in these gliomas and a non-random distribution of the mutation types within 
the tumor entities. IDH1 mutations of the R132C type are strongly associated with astrocytoma while 
IDH2 mutations predominantly occur in oligodendroglial tumors of WHO grade III.  
 
 
 
 
 
 
 
 
Keywords: IDH1, IDH2, mutation, glioma, astrocytoma, oligodendroglioma, oligoastrocytoma 
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Introduction 
 
Extraordinary high rates of spontaneous mutations in the gene encoding cytosolic NADP+ dependent 
isocitrate dehydrogenase (IDH1) have been reported in diffuse gliomas of World Health Organization 
(WHO) grades II and III of astrocytic and oligodendroglial lineages [1, 8, 17, 21] and in lower 
frequency mutations in the gene encoding mitochondrial NADP+ dependent isocitrate dehydrogenase 
(IDH2) [21]. In contrast, mutations of IDH1 are rare in primary glioblastoma [1, 2, 8, 9, 14, 17, 21]. 
These mutations appear to be of significant importance for survival of patients. Both, patients with 
anaplastic astrocytoma and glioblastoma show significantly longer overall survival in the presence of 
IDH1 or IDH2 mutations [21]. Analysis of a prospective study demonstrated that absence of IDH1 
mutations in anaplastic astrocytoma, oligoastrocytoma and oligodendroglioma of WHO grade III is a 
strong indicator for poor prognosis [20]. 
Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate. 
Five genes encoding human isocitrate dehydrogenases have been identified. IDH1 on 2q33.3 
encodes cytosolic NADP+ specific isocitrate dehydrogenase [13]. IDH1 is configured as a homodimer 
with two enzymatically active sites and most of its activity is detected in the cytosol and in 
peroxysomes [4]. A major function of IDH1 is believed to be the synthesis of NADPH required for 
reducing reactions and for lipid synthesis [16]. IDH2 on 15q26.1 encodes the mitochondrial NADP+ 
specific isocitrate dehydrogenase [5]. Similar to IDH1, this enzyme functions as a homodimer. Recent 
findings suggest that the IDH2 may be the main catalyst for the oxidation of isocitrate to α-
ketoglutarate in the citric acid cycle [6]. IDH3 is composed of three subunits encoded by IDH3A 
(subunit alpha), on 15q25.1-q25.2 [7], by IDH3B (subunit beta) on 20p13 [10] and by IDH3G (subunit 
gamma), on Xq28. IDH3 is a multi-tetrameric enzyme (2α1β1γ) with α−subunits being catalytic and the 
β- and γ -subunits being believed to be regulatory [15, 19]. IDH3 utilizes NAD+ as a coenzyme. The 
function of IDH3 in the citric acid cycle is well established. 
Glioma-specific mutations in IDH1 always affected the amino acid arginine in position 132 of the 
amino acid sequence which belongs to an evolutionary highly conserved region located at the binding 
site for isocitrate [14]. Mutations in IDH2 were exclusively detected in arginine at position 172 which is 
the analogous site to arginine 132 in IDH1 [21]. Mutations in both, IDH1 and IDH2 are heterozygous 
and of somatic origin. The role of IDH1 mutations in tumor biology currently is intensely studied. 
Mutations inactivate enzyme activity [21]. This inactivation is due to impaired substrate affinity, and 
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moreover, IDH1 mutations exert a dominant negative effect rendering heterodimers inactive as well 
[22]. Enzyme deficiency results in depletion of α-ketoglutarate which is required for prolylhydroxylases 
promoting degradation of hypoxia inducible factor 1α (HIF-1α). Increased HIF-1α levels in gliomas 
carrying the IDH1 R132H mutations have been demonstrated [22]. However, there are many other 
oxygenases which are dependent on α-ketoglutarate and which are involved in different processes 
such as histone modification or fatty acid metabolism [11]. Therefore, several other tumor relevant 
mechanisms besides HIF-1α stabilization may result from IDH1 mutation mediated depletion of α-
ketoglutarate.  
In order to determine the different types of mutations and their frequencies, we examined 1010 human 
gliomas for mutations in codons 132 and 172 in the genes for IDH1 and IDH2, respectively. Because 
high frequencies of IDH1 mutations have been described only in few glioma subtypes, we focussed in 
the present study on these entities including WHO grade II and III astrocytomas, oligodendrogliomas 
and oligoastrocytomas  
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Material and Methods 
 
Tumor specimens average patient age and sex ratio 
DNA samples from human brain tumors diagnosed at the Departments of Neuropathology of the 
Universities Heidelberg, Bonn, Düsseldorf, Nijmegen, Magdeburg and at the Charité Berlin were 
analyzed. All tumors were diagnosed and classified according to the WHO classification of tumors of 
the nervous system [12]. The series consisted of 1010 diffuse gliomas including 227 diffuse 
astrocytomas WHO grade II (A II), 228 anaplastic astrocytomas WHO grade III (A III), 128 
oligodendrogliomas WHO grade II (O II), 174 anaplastic oligodendrogliomas WHO grade III (O III), 76 
oligoastrocytomas WHO grade II (OA II) and 177 anaplastic oligoastrocytomas (OA III). The IDH1 
mutation data of 281 patients in this series have been reported in a preceding study [1].The average 
mean ages and female to male sex ratios were for A II 37 years and 44% to 56%, for A III 42 years 
and 40% to 60 %, for O II 44 years and 43% to 57%, for O III 49 years and 47% to 53%, for OA II 43 
years and 62% to 38% and for OA III 47 years and 45% to 55%.  
 
PCR amplification: 
Primer design was based on accession numbers NM_005896 for IDH1 and NM_002168 for IDH2 
(http://www.ncbi.nlm.nih.gov). A fragment of 129 bp length spanning the sequence encoding the 
catalytic domain of IDH1 including codon 132 was amplified using 60 ng each of the sense primer 
IDH1f CGGTCTTCAGAGAAGCCATT and the antisense primer IDH1r 
GCAAAATCACATTATTGCCAAC. PCR using standard buffer conditions, 20 ng of DNA and GoTaq 
DNA Polymerase (Promega, Madison, WI, USA) employed 35 cycles with denaturing at 95° C for 30 
sec, annealing at 56° C for 40 sec and extension at 72° C for 50 sec in a total volume of 15 µl. 
For confirmation, the sense primer IDH1fc ACCAAATGGCACCATACGA and antisense primer IDH1rc 
TTCATACCTTGCTTAATGGGTGT generating a 254 bp fragment at the same PCR conditions were 
employed. 
A fragment of 150 bp length spanning the sequence encoding the catalytic domain of IDH2 including 
codon 172 was amplified using 60 ng each of the sense primer IDH2f AGCCCATCATCTGCAAAAAC 
and the antisense primer IDH2r CTAGGCGAGGAGCTCCAGT. PCR using standard buffer conditions, 
20 ng of DNA and GoTaq DNA Polymerase (Promega,Madison, USA) employed 35 cycles with 
Hartmann et al.,   page 7 
denaturing at 95° C for 30 sec, annealing at 58° C for 40 sec and extension at 72° C for 50 sec in a 
total volume of 15 µl. 
For confirmation, the sense primer IDH2fc GCTGCAGTGGGACCACTATT and antisense primer 
IDH2rc TGTGGCCTTGTACTGCAGAG generating a 293 bp fragment at the same PCR conditions 
were employed. 
 
Direct sequencing: 
Two µl of the PCR amplification product was subjected sequencing using the BigDye Terminator v3.1 
Sequencing Kit (Applied Biosystems, Foster City, CA, USA). Twenty-five cycles were performed 
employing 12 ng of the sense primers IDH1f CGGTCTTCAGAGAAGCCATT or IDH2f 
CTAGGCGAGGAGCTCCAGT, with denaturing at 95° C for 30 sec, annealing at 56° for 15 sec and 
extension at 60° C for 240 sec. In case of ambiguous readings, a second round of sequencing 
analysis was performed using the antisense primer IDH1rc TTCATACCTTGCTTAATGGGTGT or 
IDH2rc TTCATACCTTGCTTAATGGGTGT and the sequencing reaction conditions as described 
above. Sequences were determined using the semiautomated sequencer (ABI 3100 Genetic Analyzer, 
Applied Biosystems) and the Sequence Pilot version 3.1 software (JSI-Medisys, Kippenheim, 
Germany). 
 
Statistics: 
The Fisher exact test was used to examine associations between nominal variables referring to 
absence or presence of genetic alterations. The relationship of IDH mutations with patient age was 
examined by student t test.  
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Results and Discussion 
 
We detected 716 IDH1 mutations and 31 IDH2 mutations in 1010 patients with astrocytoma, 
oligodendroglioma or oligoastrocytoma of WHO grades II and III. Only codon 132 of IDH1 and codon 
172 of IDH2 were affected by mutations. Previous studies did not detect IDH1 and IDH2 mutations in 
constitutional tissues [1, 8, 14, 17, 21]. Therefore we did not analyze corresponding blood samples 
from the glioma patients included in this study. In the majority of the cases, mutations in codon 132 of 
IDH1 and codon 172 of IDH2 were obvious upon sequencing in forward direction. However, we 
encountered cases yielding only weak peaks in addition to the signal of the wild type sequence. These 
cases suspected to carry a mutation were sequenced a second time in reverse direction. 
Reappearance of an additional signal at the site of suspect was then scored as positive for mutation. 
Based on direct sequencing, all mutations appeared to be heterozygous meaning that in each tumor 
with a mutation only one of the two gene copies of IDH1 or IDH2, respectively, was altered.  
 
Type and frequency of IDH1 and IDH2 mutations 
The predominant amino acid sequence alteration in IDH1 was R132H accounting for 92.7% of the 
detected mutations followed by R132C for 4.1%, R132S for 1.5%, R132G for 1.4% and R132L for 
0.2% of all IDH1 mutations. Type and distribution of the mutations are given in Table 1. We did not 
detect the R132V mutation reported and illustrated in our previous series [1]. The distribution of 
mutations in the present series matches well with those of other studies demonstrating the vast 
majority of IDH1 mutations being of the R132H type followed by R132C. The discrepancies in 
literature regarding the low frequencies of R132S, R132G and R132L may be due to differences in 
sample size and different types of tumors analyzed. 
In IDH2 the distribution of mutation types is less off-centre. R172K made up 65%, R172M amounted to 
19% and the previously not described R172W to 16% of all IDH2 mutations. In contrast to the initial 
report on IDH2 mutations, we did not find the R172G exchange. While in several instances we did 
detect a shallow G peak in nucleotide position 514, we interpreted this signal as artificial and caused 
by the flanking G nucleotides in positions 511, 512, 515 and 516 of the wild type sequence of IDH2. 
An example for such a signal interpreted as sequencing artefact is shown in Figure 1. 
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The amino acid sequence of IDH1 and IDH2 at the sites of mutations are identical while the nucleotide 
sequences differ. It is noteworthy that the most frequent mutations in both, IDH1 and IDH2 derive from 
a G to A transition in nucleotide position 395 of IDH1 and 515 of IDH2, respectively. 
 
IDH1 and IDH2 mutations in astrocytoma, oligodendroglioma and oligoastrocytoma 
We detected 716 IDH1 mutations in our series. Type and distribution of the mutations are given in 
Table 2. A II carried mutations in 72.7% comparing well with frequencies of 74% [1], 83% [21], 88% 
[17] and 59% [8] reported in previous studies. IDH1 mutations in A III were observed in 64.0% 
comparable to 62% [1], 69% [21], 78% [17] and 52% [8] in earlier studies. The present frequency was 
for O II 82,0% comparing to 71% [1], 82% [21], 79% [17] and 68% [8] and for O III 69.5% comparing to 
67% [1], 86% [21], 75% [17] and 60% [8]. OA II carried IDH1 mutations in 81.6 % comparing to 78% 
[1], 100% [21], 94% [17] and 50% [8] and OA III in 66.1% while the previous studies detected 
mutations in 78% [1], 100% [21],71% [17] and 78% [8]. Thus, the frequencies in the present study are 
very similar to our previous series but slightly lower than those reported by others. This difference may 
in part be attributed to small numbers of particular subtypes of gliomas in the other studies, however, 
the use of different thresholds in scoring weaker signals as sufficient for a mutation may also play a 
role. Glioma tissues always contain a non-neoplastic cell compartment including vascular cells, 
reactive astrocytes, lymphocytes and microglial cells. In addition, the diffuse and infiltrative nature of 
glioma frequently results in a substantial fraction of residual brain in the tissue samples. Therefore, the 
mutant signal in gliomas heterozygous for mutations usually is less intense than the wild type signal 
requiring a more or less arbitrary threshold level to separate between a signal indicating a mutation 
and a background peak. 
Mutations in IDH2 mutations were much less common than those in IDH1. We found 31 IDH2 
mutations in our series. A II and A III carried IDH2 mutation in 0.9% each while 4.7% of O II, 5.3% of O 
III, 1.3% of OA II and 5.1% of OA III had IDH2 mutations. Type and distribution of the mutations are 
given in Table 3. A II carried IDH2 mutations in 0.9% which is considerably lower than the frequency of 
7% previously observed [21]. Mutations in A III were observed in 0.9% and thus were also less 
frequent than the 4% reported in the preceding study [21]. The present frequency for O II and O III 
were 4.7% and 5.3% comparing well to 4% and 8% [21]. OA II and OA III carried mutations in 1.3% 
and 5.1% and have not previously been reported.  
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IDH1 R132C mutations associate with astrocytoma of WHO grade II 
IDH1 mutations exhibited a non-random distribution among astrocytic and oligodendroglial tumors. In 
our previous study, we hinted at a trend for R132C mutations to favour astrocytomas. In the present 
series, a total of 29 R132C mutations were observed in 17 A II, 7 A III, 2 O III and 1 OA II and OA III 
each. This distribution favouring astrocytomas was highly significant (p < 0,0001). The significance of 
the association of R132C with astrocytoma is further supported by a recent report. In a series of Li-
Fraumeni patients with astrocytoma, only R132C mutations in IDH1 but not the much more frequent 
R132H mutation were observed [18]. Because sporadic astrocytomas carry somatic mutations in the 
TP53 gene much more frequently than oligodendrogliomas and oligoastrocytomas, and because Li-
Fraumeni patients by definition have a germ line mutation in TP53, there seems to be an association 
of the IDH1 R132C mutation with mutations in TP53. Whether and how TP53 mutations favour the 
occurrence of IDH R132C mutations, as supported in the Li-Fraumeni setting, or whether IDH1 
mutations favour subsequent TP53 mutations, as suggested by the significantly higher incidence of 
IDH1 mutations than the one of TP53 mutations in sporadic astrocytomas, remains yet unresolved. 
R132C mutations were more frequent in WHO grade II tumors than in WHO grade III tumors (p < 
0.05). 
 
IDH2 mutations associate with oligodendroglial tumors and with the WHO grade III 
In our series, IDH2 mutations predominantly occurred in tumors with an oligodendroglial component. 
Six O II, 9 O III, 1 OA II and 9 OA III but only 2 A II and A III each carried IDH2 mutations (p < 0.001). 
This partially contrasts the initial report of IDH2 mutations in gliomas [21] reporting 2/51 O II, 3/36 O 
III, but also 2/30 A II and 2/52 A III with IDH2 mutations. OA II and OA III were not analyzed for IDH2 
in that study. Our findings are very similar with regard to O II and O III, however, they are different 
from those reported for A II and A III. Divergent results may to some extent be explained by the 
considerable interobserver variability in the distinction of astrocytoma from oligoastrocytoma [3]. The 
WHO criteria do allow for a significant diagnostic overlap [12] and the problem is further aggravated by 
tissue sampling with usually only parts of the tumor tissue being available for histological analysis. 
Another reason for this discrepancy may be our threshold in scoring mutations resulting in elimination 
of all R172G mutations reported previously. 
In our series 22 of 33 IDH2 mutations occurred either in A III, O III or OA III. This represents an 
association with anaplastic tumors (p < 0.05). While there is no doubt that IDH1 mutations occur early 
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in tumor formation, because the majority of A II, O II and OA II already harbour this alteration, the time 
point of the occurrence of IDH2 mutations cannot definitely be set at a similar early point. In fact, the 
data are also compatible with IDH2 mutations being associated with tumor progression. 
 
IDH1 and IDH2 are inversely associated 
In the initial report on IDH2 mutations, only glioma samples not carrying IDH1 mutations were 
analyzed for IDH2 [21]. In order to analyze the potentially complementary effects of these mutations, 
we examined our entire series for both IDH1 and IDH2 mutations. We detected 712 tumors with an 
IDH1 mutation but wild type for IDH2, 27 tumors with IDH2 mutation but wild type for IDH1 and only 4 
tumors, 1 A III, 1 O III and 2 OA III, characterized by both, IDH1 and IDH2 mutations. Interestingly the 
4 tumors with mutations in both IDH1 and IDH2 were all anaplastic gliomas. This clearly is a non 
random distribution (p < 0.00001). Such partition indicates that either IDH1 or IDH2 mutations 
independently provide a growth advantage for mutant cells and that one of them is sufficient to 
mediate this advantage. The presence of IDH2 mutations predominately in anaplastic tumors may 
indicate that these mutations constitute a progression-associated alteration which promotes more 
aggressive tumor growth. However, in this case more than only 4 tumors with both, IDH1 and IDH2 
mutations would have been expected in our series if these mutations arose independent from each 
other. 
 
IDH1 and IDH2 mutations and age 
In patients under the age of 18 years, IDH1 mutations were rare occurring in only 4 of 32 (12.5%) 
tumors and IDH2 mutations were absent. This finding suggests that paediatric astrocytomas, 
oligodendrogliomas and oligoastrocytomas genetically differ from their adult counterparts. The mean 
age of adult patients aged 18 or older with anaplastic gliomas of WHO grades III carrying IDH1 
mutations was 43.9 years while anaplastic glioma patients without mutations averaged 50.6 years (p < 
0.0001). In all three groups, A III, O III and OA III patients with mutations on average were younger 
than patients without mutations (A III: p < 0.01, O III: not significant, OAIII: p < 0.01). The average age 
of patients with gliomas of WHO grade II carrying IDH1 mutations was 41.3 years while glioma 
patients without mutations averaged 42.8 years (not significant). In all three groups, A II, O II and OA II 
patients with mutations on average were older than patients without mutations (not significant). 
Patients carrying the most common R132H mutation averaged 42.9 years while patients with the 
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R132C mutation were significantly younger averaging 34.9 years (p < 0.01), those with the R132G 
mutation were 37.9 years old (not significant) and those carrying R132S averaged 36.2 years (p < 
0.01).  
 
Conclusions 
The present study provides a reliable basis for the frequencies and types of IDH1 codon 132 and IDH2 
codon 172 mutations in diffusely infiltrating astrocytomas, oligodendrogliomas and oligoastrocytomas 
of WHO grades II and III. The data confirm a high frequency of IDH1 mutation in these tumors, with 
70.9 % of all investigated tumors carrying an IDH1 codon 132 mutation, most commonly of the R132H 
type. In contrast, IDH2 mutations were restricted to 3.1% of the tumors. Our data confirm a mutually 
exclusive presence of either IDH1 or IDH2 mutation in gliomas. Furthermore, we show that the R132C 
IDH1 mutation is significantly associated with astrocytic histology, while IDH2 mutations are more 
common in oligodendroglial tumors as compared to astrocytomas. In addition, IDH2 mutation was 
more common in anaplastic gliomas of WHO grade III as compared to WHO grade II. Further studies 
need to address the clinical impact of the individual IDH1 and IDH2 mutations with respect to their 
potential role as prognostic markers in patients with diffuse gliomas. 
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Figure 1 
 
 
 
 
 
 
 
Example for a sequence with a small G – signal at nucleotide position 394 of IDH2, which we did not 
score as evidence for a point mutation but rather considered as a sequencing artefact due to stuttering 
of polymerase induced by the flanking G signals  
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Table 1 
 
 
Type of 716 IDH1 and 31 IDH2 mutations and frequency among mutations in 1010 WHO grade II and 
III astrocytomas, oligodendrogliomas and oligoastrocytomas 
 
 
Gene Nucleotide 
change 
 
Amino acid 
change 
N (%) 
    
IDH1 G395A R132H 664 (92.7%) 
 C394T R132C 29 (4.2%) 
 C394A R132S 11 (1.5%) 
 C394G R132G 10 (1.4%) 
 G395T R132L 2 (0.2%) 
    
IDH2 G515A R172K 20 (64.5%) 
 G515T R172M 6 (19.3%) 
 A514T R172W 5 (16.2%) 
    
 
 
N (%) = number of tumors and percentage of mutation among all mutations 
 
 
Table 2  
 
716 IDH1 codon 132 mutations in 1010 WHO grade II and III astrocytomas, oligodendrogliomas and oligoastrocytomas of WHO grades II and III 
 
 
Amino acid 
exchange 
All tumors 
N = 1010 
A II 
N = 227 
A III 
N = 228 
O II 
N = 128 
O III 
N = 174 
OA II 
N = 76 
OA III 
N = 177 
        
R132H 664 (61.7%) 143 (63.0%) 132 (57.9%) 103 (80.5%) 111 (63.8%) 60 (78.9%) 115 (65.0%) 
R132C 29 (2.9%) 17 (7.5%) 7 (3.1%) 0 (0%) 2 (1.1%) 1 (1.3%) 1 (0.6%) 
R132S 11 (1.1%) 3 (1.3%) 3 (1.3%) 2 (1.5%) 4 (2.3%) 0 0 
R132G 10 (1.0%) 2 (0.9%) 3 (1.3%) 0 3 (1.7%) 1 (1.3%) 1 (0.6%) 
R132L 2 (0.2%) 0  1 (0.4%) 0 1 (0.6%) 0 0 
        
all 716 (70.9%) 165 (72.7%) 146 (64.0%) 105 (82.0%) 121 (69.5%) 62 (81.6%) 117 (66.1%) 
 
 
N number of tumors analyzed 
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Table 3 
 
31 IDH2 codon 172 mutations in 1010 WHO grade II and III astrocytomas, oligodendrogliomas and oligoastrocytomas of WHO grades II and III 
 
 
Amino acid 
exchange 
All tumors 
N = 1010 
A II 
N = 227 
A III 
N = 228 
O II 
N = 128 
O III 
N = 174 
OA II 
N = 76 
OA III 
N = 177 
        
R172K 20 (2.0%) 2 (0.9%) 2 (0.9%) 3 (2.3%)    6 (3.4%) 1 (1.3%) 6 (3.4%)
R172M        6 (0.6%) 0 0 1 (0.8%) 2 (1.1%) 0 3 (1.7%)
R172W        5 (0.5%) 0 0 2 (1.6%) 1 (0.6%) 0 2 (1.1%)
        
all 31 (3.1%) 2 (0.9%) 2 (0.9%) 6 (4.7%) 9 (5.3%) 1 (1.3%) 9 (5.1%) 
 
 
N number of tumors analyzed 
 
 
 
